Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuon Therapeutics, a clinical stage biotechnology company focused on novel therapies for autoimmune and chronic inflammatory diseases and pain, has completed a $27 million series B financing led by Frazier Healthcare Ventures and Domain Associates.
Subscribe to our email newsletter
The series B funding will enable Nuon Therapeutics to advance its orally active lead compound, tranilast, through Phase II clinical trials and support the discovery and development of additional compounds. Nuon Therapeutics’s strategy is to develop tranilast in new clinical indications covered by its intellectual property, as well as build a portfolio of additional drugs in autoimmune disease and pain.
Rodney Pearlman, CEO of Nuon Therapeutics, said: “We are pleased to have such a well-regarded syndicate of investors backing our development activities. These firms have extensive experience with biotechnology companies at our stage and we look forward to utilizing their expertise and support as we move tranilast into new clinical applications.”